Question 1

What is N-803?

Accepted Answer

N-803 is a Other.

Question 2

How often does N-803 appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 9 articles.

Question 3

When was N-803 first tracked by Ergen?

Accepted Answer

First tracked on May 20, 2026.

Question 4

When was N-803 last mentioned in news?

Accepted Answer

Last active on May 20, 2026.

Question 5

What is N-803's current news sentiment?

Accepted Answer

Aggregate sentiment score: 50 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is N-803 in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving N-803?

Accepted Answer

MiNK Therapeutics agenT-797 Data (May 20, 2026, 9 articles).

Question 8

How did the "MiNK Therapeutics agenT-797 Data" event impact N-803?

Accepted Answer

N-803, also known as Anktiva, is an FDA-approved IL-15 superagonist developed by ImmunityBio, used in combination with Agent 797 in the reported clinical case.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.